Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Календарь
Скринер
Новости
О нас

AMIX - Autonomix Medical, Inc. Последние новости | Finranks

Home

/

AMIX

A

Autonomix Medical, Inc. (AMIX)

NCM – Цена в реальном времени. Валюта: USD

7.93

-1.19 (-13.05%)

Рынок открыт: Aug 12, 2026, 12:34 PM EDT

9.00

-0.12 (-1.34%)

Предыдущая сессия: Aug 11, 2026, 7:59 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Autonomix Medical Completes Good Laboratory Practice (GLP) Preclinical Study, Marking Key Step Toward FDA Submission

Autonomix Medical Completes Good Laboratory Practice (GLP) Preclinical Study, Marking Key Step Toward FDA Submission

Final histology and laboratory analyses support the study's safety and performance objectives THE WOODLANDS, TX, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the successful completion of its Good Laboratory Practice (GLP) pre-clinical study, a significant regulatory milestone supporting the Company's submission to the U.S. Food and Drug Administration (FDA). The study was conducted in accordance with FDA Good Laboratory Practice standards and evaluated the safety, functionality and performance of the Autonomix platform across multiple clinically relevant anatomical targets in porcine models.

Autonomix Medical Congratulates Co-Founder & Chief Medical Officer Dr. Robert Schwartz on Receiving Prestigious 2026 Cardiovascular Tech Forum Lifetime Achievement Award

Autonomix Medical Congratulates Co-Founder & Chief Medical Officer Dr. Robert Schwartz on Receiving Prestigious 2026 Cardiovascular Tech Forum Lifetime Achievement Award

Recognition honors one of the medical technology industry's most influential innovators, whose career has helped shape modern cardiovascular care

Autonomix Stock Skyrockets After Obtaining Key Cancer Tech Patent

Autonomix Stock Skyrockets After Obtaining Key Cancer Tech Patent

Autonomix Medical Inc. (NASDAQ:AMIX) shares are skyrocketing Tuesday afternoon after securing U.S. Patent No. 12,433,670.

Autonomix Medical Expands Precision Neuromodulation Platform with Broad New U.S. Patent Supporting Nerve Sensing, Mapping and Targeted Therapy

Autonomix Medical Expands Precision Neuromodulation Platform with Broad New U.S. Patent Supporting Nerve Sensing, Mapping and Targeted Therapy

Patent expands protection for technology designed to sense, map and selectively target nerves associated with tumors and cancer-related pain

Видео

No Data

There is no data to display

Пресс-релизы

Autonomix Medical Completes Good Laboratory Practice (GLP) Preclinical Study, Marking Key Step Toward FDA Submission

Autonomix Medical Completes Good Laboratory Practice (GLP) Preclinical Study, Marking Key Step Toward FDA Submission

Final histology and laboratory analyses support the study's safety and performance objectives THE WOODLANDS, TX, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the successful completion of its Good Laboratory Practice (GLP) pre-clinical study, a significant regulatory milestone supporting the Company's submission to the U.S. Food and Drug Administration (FDA). The study was conducted in accordance with FDA Good Laboratory Practice standards and evaluated the safety, functionality and performance of the Autonomix platform across multiple clinically relevant anatomical targets in porcine models.

Autonomix Medical Congratulates Co-Founder & Chief Medical Officer Dr. Robert Schwartz on Receiving Prestigious 2026 Cardiovascular Tech Forum Lifetime Achievement Award

Autonomix Medical Congratulates Co-Founder & Chief Medical Officer Dr. Robert Schwartz on Receiving Prestigious 2026 Cardiovascular Tech Forum Lifetime Achievement Award

Recognition honors one of the medical technology industry's most influential innovators, whose career has helped shape modern cardiovascular care

Autonomix Medical Expands Precision Neuromodulation Platform with Broad New U.S. Patent Supporting Nerve Sensing, Mapping and Targeted Therapy

Autonomix Medical Expands Precision Neuromodulation Platform with Broad New U.S. Patent Supporting Nerve Sensing, Mapping and Targeted Therapy

Patent expands protection for technology designed to sense, map and selectively target nerves associated with tumors and cancer-related pain